GPHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
GPHARMA
Largest movements
No asset line moved by more than 1% of the balance sheet total.
- Debts after one year -€125,999
down €125,999 (-11.4%), from €1.1m to €975,466
- Profit (loss) carried forward +€52,848
up €52,848 (+74.8%), from €70,649 to €123,496
- Current portion of long-term debt +€47,465
up €47,465 (+60.4%), from €78,534 to €125,999
- Financial charges +€44,594
up €44,594 (+1,306%), from €3,415 to €48,009
- Gross operating margin +€22,296
up €22,296 (+24.2%), from €92,018 to €114,314
- Taxes -€4,497
down €4,497 (-25.0%), from €17,954 to €13,457
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,659,829 | €1,664,758 | +€4,929 | +0.3% |
| Fixed assets | 21/28 | €1,550,000 | €1,550,000 | = | 0.0% |
| Financial fixed assets | 28 | €1,550,000 | €1,550,000 | = | 0.0% |
| Current assets | 29/58 | €109,829 | €114,758 | +€4,929 | +4.5% |
| Amounts receivable within one year | 40/41 | €6 | €338 | +€332 | +5,583% |
| Trade receivables | 40 | €0 | €338 | +€338 | |
| Other amounts receivable | 41 | €6 | €0 | -€6 | -100% |
| Cash at bank and in hand | 54/58 | €109,823 | €114,420 | +€4,597 | +4.2% |
| Total equity and liabilities | 10/49 | €1,659,829 | €1,664,758 | +€4,929 | +0.3% |
| Equity | 10/15 | €170,649 | €223,496 | +€52,848 | +31.0% |
| Contributions | 10/11 | €100,000 | €100,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €70,649 | €123,496 | +€52,848 | +74.8% |
| Amounts payable | 17/49 | €1,489,180 | €1,441,262 | -€47,918 | -3.2% |
| Amounts payable after more than one year | 17 | €1,101,466 | €975,466 | -€125,999 | -11.4% |
| Financial debts | 170/4 | €1,101,466 | €975,466 | -€125,999 | -11.4% |
| Amounts payable within one year | 42/48 | €387,715 | €465,796 | +€78,081 | +20.1% |
| Current portion of amounts payable after more than one year | 42 | €78,534 | €125,999 | +€47,465 | +60.4% |
| Trade debts | 44 | €0 | €215 | +€215 | |
| Suppliers | 440/4 | €0 | €215 | +€215 | |
| Taxes, remuneration and social security | 45 | €26,328 | €40,179 | +€13,851 | +52.6% |
| Taxes | 450/3 | €26,328 | €40,179 | +€13,851 | +52.6% |
| Other amounts payable | 47/48 | €282,852 | €299,402 | +€16,550 | +5.9% |
| Gross operating margin | 9900 | €92,018 | €114,314 | +€22,296 | +24.2% |
| Operating profit (loss) | 9901 | €92,018 | €114,314 | +€22,296 | +24.2% |
| Financial charges | 65/66B | €3,415 | €48,009 | +€44,594 | +1,306% |
| Recurring financial charges | 65 | €3,415 | €48,009 | +€44,594 | +1,306% |
| Profit (loss) for the period before taxes | 9903 | €88,603 | €66,305 | -€22,298 | -25.2% |
| Income taxes | 67/77 | €17,954 | €13,457 | -€4,497 | -25.0% |
| Profit (loss) for the period | 9904 | €70,649 | €52,848 | -€17,801 | -25.2% |
| Profit (loss) for the period to be appropriated | 9905 | €70,649 | €52,848 | -€17,801 | -25.2% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 17 October 2026 via checked.be.